0 1 7 ) A 8 5 3 -A 9 4 3 A867 generated a tornado diagram, and a two-way deterministic one considering the two key parameters that differentiate CRRT from IRRT: the daily implementation cost difference and the cumulative risk of dialysis dependence. We used the threshold of 3 times per capita GDP, that is, R $ 84,741 (3 X R $ 28,247) as the threshold for cost-effectiveness. Results: CRRT is dominant vs. IRRT from 18 months of treatment. Based our assumptions, the cohort of patients initially treated with CRRT had better clinical outcomes QALY´s and lower total costs of treatment. Patients treated with CRRT are more likely to recover renal function. ConClusions: CRRT when compared to IRRT can be considered a dominant therapy, that is, it offers better outcomes and lower total treatment costs, under the perspective of the private healthcare system in Brazil.

No abstract